Press release
Major Advancements Of Type 2 Diabetes Mellitus : GPCRs and Protein Kinases Dominate Pipeline 2017
Albany, NY, 1st December : Recent research and the current scenario as well as future market potential of "Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects" globally.Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=903616
Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy.
The emergence over the past decade of glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT-2) inhibitors has intensified competition. These new drug classes have been highly commercially successful and are now well established within the treatment algorithm.
In spite of these developments, there are still significant unmet needs for T2DM, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the large T2DM pipeline, with a diverse range of first-in-class targets identified.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/frontier-pharma-type-2-diabetes-mellitus-gpcrs-and-protein-kinases-dominate-pipeline-with-most-promising-firstinclass-targets-demonstrating-potential-diseasemodifying-effects-report.html/toc
Scope
The escalating T2DM public healthcare need has resulted in a competitive market landscape
What is the pathophysiology of T2DM?
What are the common co-morbidities and complications?
How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
What are the most significant unmet needs within the market?
The T2DM pipeline is large and innovative
Which molecule types and molecular targets are most prominent within the pipeline?
Which first-in-class targets are most promising?
How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
The T2DM deals landscape is highly active
Do T2DM products attract high deal values?
Which molecule types and molecular targets dominate the deals landscape?
Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?
Reasons to buy
This report will allow you to
Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.
Browse Report @ https://www.researchmoz.us/frontier-pharma-type-2-diabetes-mellitus-gpcrs-and-protein-kinases-dominate-pipeline-with-most-promising-firstinclass-targets-demonstrating-potential-diseasemodifying-effects-report.html
Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Major Advancements Of Type 2 Diabetes Mellitus : GPCRs and Protein Kinases Dominate Pipeline 2017 here
News-ID: 840992 • Views: …
More Releases from Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominat …
Researchmoz added Most up-to-date research on "Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas" to its huge collection of research reports.
Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence is on the rise, alongside increases in obesity due to lifestyle changes in the 21st century.
Type 2…

Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominat …
Researchmoz added Most up-to-date research on "Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease" to its huge collection of research reports. An insight on the important factors and trends influencing the market.
Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The…

Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominat …
Researchmoz added Most up-to-date research on "Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease" to its huge collection of research reports.
Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease
Summary
Type 2 diabetes mellitus (T2DM) is a…
More Releases for T2DM
Type 2 Diabetes Mellitus Therapeutics Market Forecasts to 2023 Explored in Lates …
ResearchMoz include new market research report "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" to its huge collection of research reports.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. Chronic…
Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 | Now A …
Researchmoz added Most up-to-date research on "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" to its huge collection of research reports.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This…
Latest Research Report on Type 2 Diabetes Mellitus Therapeutics in Major Develop …
Researchmoz added Most up-to-date research on "Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth" to its huge collection of research reports.
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed…
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate P …
Albany, NY, Feb 27, 2017: Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and…
Diabetes & Obesity Drug Development Pipeline Review, T2DM pipeline will continue …
Worldwide Market studies the current scenario as well as future market potential of "Diabetes & Obesity Drug Development Pipeline Review, 2016"
The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do…
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs And Protein Kinases Dominate P …
Recent research and the current scenario as well as future market potential of "Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs And Protein Kinases Dominate Pipeline, With Most Promising First-In-Class Targets Demonstrating Potential Disease-Modifying Effects" globally.
Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.
Global prevalence of…